A
Alexandra Giatromanolaki
Researcher at Democritus University of Thrace
Publications - 360
Citations - 26647
Alexandra Giatromanolaki is an academic researcher from Democritus University of Thrace. The author has contributed to research in topics: Angiogenesis & Cancer. The author has an hindex of 66, co-authored 340 publications receiving 22956 citations. Previous affiliations of Alexandra Giatromanolaki include John Radcliffe Hospital.
Papers
More filters
Journal ArticleDOI
Malignant female adnexal tumour of probable Wolffian origin: criteria of malignancy
TL;DR: The recognition of this peculiar tumour arrangement may be of help in establishing the diagnosis and prognosis of patients when lymph node biopsies searching for malignancy are so common in the pathologist’s routine practice.
Journal ArticleDOI
'Stemness' and 'senescence' related escape pathways are dose dependent in lung cancer cells surviving post irradiation.
Avgi Tsolou,Ioannis Lamprou,Alexandra-Ourania Fortosi,Maria Liousia,Alexandra Giatromanolaki,Michael I. Koukourakis +5 more
TL;DR: Cancer cells surviving after radiotherapy may follow two different escape pathways: selection for radioresistance resulting in regrowth, and in clinical terms relapse, or above an irradiation threshold, stem-cells die and cancer cells become senescent, leading the tumor to a state of dormancy.
Journal ArticleDOI
Increased Soluble PD-L1 Levels in the Plasma of Patients with Epithelial Ovarian Cancer Correlate with Plasma Levels of miR34a and miR200.
Michael I. Koukourakis,Emmanuel N Kontomanolis,Maria Sotiropoulou,Achilleas Mitrakas,Evangelia Dafa,Stamatia Pouliliou,Efthimios Sivridis,Alexandra Giatromanolaki +7 more
TL;DR: As well as cancer cell expression of PD-L1, a high sPD-L 1 level characterizes a subset of patients with ovarian cancer, and the value of this latter feature as a biomarker for the administration of anti-PD- L1/PD1 therapy needs further evaluation.
Journal ArticleDOI
Tumor draining lymph nodes, immune response, and radiotherapy: Towards a revisal of therapeutic principles.
TL;DR: In this article , the authors present the biological and clinical role of tumor-draining lymph nodes and propose strategies to include in the design of immuno-radiotherapy trials aiming to eradicate cancer at a local and distant level.
Journal ArticleDOI
c-erbB-2 and episialin challenge host immune response by HLA class I expression in human non-small-cell lung cancer.
Michael I. Koukourakis,Alexandra Giatromanolaki,Francesca Guddo,Loukas Kaklamanis,Maurizio Vignola,Stelios Kakolyris,Hellen Turley,V. Georgoulias,Giovanni Bonsignore,Kevin C. Gatter,Adrian L. Harris +10 more
TL;DR: Evidence is provided that the sequence of cell adhesion-disrupting oncoprotein expression, HLA class I induction, and enhanced epitope presentation followed by lymphocytic response is an important pathogenetic three-step sequence of events that define, in part, the clinical outcome in non-small-cell lung cancer.